Jeff Settleman, PhD
Head of Oncology Research, Calico Life Sciences
Jeff Settleman is the head of oncology research at Calico Life Sciences, an aging-focused biotechnology company in South San Francisco. His research emphasis is primarily in cancer cell biology and therapeutics.
He is especially interested in mechanisms of drug resistance and the phenotypic heterogeneity within cell populations that drives tumor evolution and the population-level response to stress. He has authored more than 200 scientific publications. He joined the Harvard Medical School faculty in 1992 and was named the school’s Laurel Schwartz Professor of Oncology in 2008. He was also the director of the Center for Molecular Therapeutics, the scientific director of the Massachusetts General Hospital Cancer Center, and the leader of the cancer cell biology program within the Dana-Farber/Harvard Cancer Center. In 2010, Jeff transitioned from academia to industry, joining Genentech as the senior director of discovery oncology, where he oversaw efforts to identify and validate targets for oncology drug discovery and to discover predictive biomarkers for new cancer therapies. He joined Calico in 2015.
He received a PhD in genetics from Yale University in 1989, conducting thesis research under the mentorship of Dan Dimaio. From 1989 to 1992 Jeff was a postdoctoral fellow at the Whitehead Institute for Biomedical Research at MIT in Robert Weinberg’s laboratory.